Medicalgorithmics S.A. closed the first quarter of 2026 with estimated consolidated sales revenue of PLN 10.2 million, representing a 51% year-on-year increase. The company also once again reported a positive estimated EBITDA result of PLN 1.0 million. During the past quarter, Medicalgorithmics signed three new agreements and expanded one of its existing partnerships to include, among other things, the distribution of VCAST technology.
“The results achieved in the past quarter confirm the full effectiveness and efficiency of our business model. We delivered results comparable to those of the record-breaking fourth quarter of 2025, even though the market environment was far from supportive. In January, the United States experienced the coldest weather in decades, which negatively affected the number of completed sessions. In addition, the war in Iran, which began in March, caused delays in negotiations for new contracts and in sales of the Kardiobeat.ai device. This strengthens our belief that these results are repeatable and that the coming quarters should deliver very strong growth dynamics while maintaining our current pace of development,” commented Dr. Kris Siemionow, CEO of Medicalgorithmics.
In the first quarter of 2026, Medicalgorithmics generated PLN 10.2 million in consolidated revenue, compared with PLN 6.8 million in the same period of the previous year. This translates into a year-on-year increase of 51%. The U.S. market generated PLN 4.7 million in revenue for the company, marking growth of 105%. These figures confirm the implementation of the company’s strategy, which focuses on the sale of high-margin AI algorithms and diagnostic software. During the reporting period, Medicalgorithmics carried out more than 112,000 ECG tests.
“In addition to fulfilling our existing contracts, including the one with one of the largest U.S. IDTFs, we continue to win new business. Last quarter, we acquired three new clients, including our first one in South America. We expect to sign two to three new contracts per quarter this year,” added Dr. Kris Siemionow.
At the beginning of January, the ECG innovation company established cooperation with U.S.-based IDTF CardioDiagnostics, which specializes in cardiology care solutions with a focus on heart monitoring and remote diagnostics through cloud software and clinical electrocardiographic monitoring devices. Under the agreement, Medicalgorithmics will provide its partner with innovative AI algorithms for ECG analysis, namely DeepRhythm AI (DRAI).
Shortly afterwards, the company entered into a breakthrough partnership with Peru-based Sharp Tech, marking its debut in the Latin American market. In March, Medicalgorithmics also signed an agreement with South Korea’s Seers Technology, under which its software and algorithms will be integrated with the partner’s hardware. The company also signed an annex to its agreement with its partner in Israel, under which the distributor will expand its offering to include, among other things, the innovative VCAST technology, as well as an order for additional Kardiobeat.ai devices worth more than PLN 650,000.
